Citation: D. Perrin et al., Expression in yeast and purification of functional recombinant human poly(ADP-ribose)polymerase (PARP). Comparative pharmacological profile with thatof the rat enzyme, J ENZ INHIB, 15(5), 2000, pp. 461-469
Authors:
van Hille, B
Etievant, C
Barret, JM
Kruczynski, A
Hill, BT
Citation: B. Van Hille et al., Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action, ANTI-CANC D, 11(10), 2000, pp. 829-841
Authors:
Etievant, C
Kruczynski, A
Barret, JM
Perrin, D
van Hille, B
Guminski, Y
Hill, BT
Citation: C. Etievant et al., F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103, CANC CHEMOT, 46(2), 2000, pp. 101-113
Authors:
Perrin, D
van Hille, B
Barret, JM
Kruczynski, A
Etievant, C
Imbert, T
Hill, BT
Citation: D. Perrin et al., F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action, BIOCH PHARM, 59(7), 2000, pp. 807-819
Citation: B. Van Hille et al., Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase II alpha and II beta isoforms, ANTI-CANC D, 10(6), 1999, pp. 551-560
Authors:
van Hille, B
Clerc, X
Creighton, AM
Hill, BT
Citation: B. Van Hille et al., Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds, BR J CANC, 81(5), 1999, pp. 800-807